Zilovertamab vedotin (ZV), an antibody drug conjugate which is capable to target the extracellular domain of ROR1, conjugated with the anti-microtubule cytotoxin monomethyl auristatin E was evaluated on 32 patients with MCL, CLL, DLBCL, follicular lymphoma, marginal zone lymphoma or Richter transformation lymphoma and showed no unexpected toxicities and antitumor activity [108]. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.